Hikma Strikes Deal For Ryaltris In US

Agreement With Glenmark Builds On Nasal Spray Portfolio

 
• By Dave Wallace

Hikma has struck a deal with Glenmark to gain US rights to its Ryaltris nasal spray. The agreement comes as Hikma reported sales ahead by 7% in 2019 on strong performances from the firm’s Injectables and Branded segments.

Specialty pharmacist
The Ryaltris deal bolsters Hikma’s specialty business • Source: Shutterstock

More from Deals

More from Business